Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the adaptive arm of immune systems during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis.

Mar 2, 2016 · PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has elicited durable antitumor responses and long-term remissions in a subset of patients with a broad spectrum of cancers. How to improve, widen, and predict the clinical response to anti-PD therapy is a central theme in the fie …

We show that the interaction of B7-1 with PD-L1 inhibits T cell activation and cytokine production by comparing responses of T cells deficient in the well-described (CD28, CTLA4, and PD-1) and newly-characterized (B7-1 and PD-L1) receptors to either B7-1-Ig or PD-L1-Ig.

Here, we propose that PD-L1:B7-1 cis-interaction brings novel mechanistic understanding of these pathways, new insights into mechanisms of current immunotherapies, and fresh ideas to develop better treatments in a variety of therapeutic settings.

Here, we propose that the PD-L1:B7-1 cis-interaction brings novel mechanistic understanding of these pathways, new insights into mechanisms of current immunotherapies, and fresh ideas to develop better treatments in a variety of therapeutic settings.

Jan 25, 2017 · In 2002, Lieping Chen discovered the critical role of B7-H1 (PD-L1) as a potential immune evasion mechanism in the tumor microenvironment. B7-H1 is found to be overexpressed in many human tumor tissues, but minimally detected in the normal tissues, which was mainly regulated by IFN-γ .

PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has elicited durable antitumor responses and long-term remissions in a subset of patients with a broad spectrum of cancers. How to improve, widen, and predict the clinical response to anti-PD therapy is a central theme in the field of cancer immunology and immuno-therapy.

Jun 20, 2019 · Programmed death ligand 1 (PD-L1, also called B7-H1) is an immune checkpoint protein that inhibits immune function through its binding of the programmed cell death protein 1 (PD-1) receptor. Clinically approved antibodies block extracellular PD-1 and PD-L1 binding, yet the role of intracellular PD-L …

Apr 3, 2025 · Programmed death-ligand 1 (PD-L1), designated as B7-H1 or CD-274, was first identified in 1999 as a constituent of the B7 family. In humans, this type I transmembrane protein is encoded by the CD274 gene, which is located on chromosome 9. It is present across a variety of immune cells that are derived from myeloid lineages, such as dendritic ...

PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has elicited durable anti-tumor responses and long-term remissions in a subset of patients with a broad spectrum of cancers. How to improve, widen, and predict the clinical ...